Cara Therapeutics Inc (CARA) Jumps 6.68% on December 31

Equities Staff |

Cara Therapeutics Inc (CARA) was among the biggest gainers on the Russell 2000 for Thursday December 31 as the stock popped 6.68% to $16.85, representing a gain of $1.055 per share. Some 434,219 shares traded hands on 2,311 trades, compared with an average daily volume of 318,255 shares out of a total float of 27.23 million. The stock opened at $16.32 and traded with an intraday range of $17.14 to $16.25.

After today's gains, Cara Therapeutics Inc reached a market cap of $458.72 million. Cara Therapeutics Inc has had a trading range between $23.61 and $9.00 over the last year, and it had a 50-day SMA of $15.43 and a 200-day SMA of $14.63.

Cara Therapeutics Inc is a clinical-stage biopharmaceutical company developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors.

Cara Therapeutics Inc is based out of Shelton, CT and has some 15 employees. Its CEO is Derek T. Chalmers.

For a complete fundamental analysis analysis of Cara Therapeutics Inc, check out’s Stock Valuation Analysis report for CARA. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Kiwa Bio-Tech Products Group Corp

Kiwa Bio-Tech Products Group Corp develops, manufactures, distributes and markets, cost-effective and environmentally safe bio-technological products for agriculture in China.

Private Markets


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…